This company has been acquired
Entasis Therapeutics Holdings Management
Management criteria checks 2/4
Key information
Manos Perros
Chief executive officer
US$2.0m
Total compensation
| CEO salary percentage | 27.0% |
| CEO tenure | 7.2yrs |
| CEO ownership | 0.2% |
| Management average tenure | 3yrs |
| Board average tenure | 4.3yrs |
Recent management updates
Recent updates
Will Entasis Therapeutics Holdings (NASDAQ:ETTX) Spend Its Cash Wisely?
Dec 16
Entasis Therapeutics: AstraZeneca Spin-Out Developing Targeted Antibacterial Products
Nov 17Is Entasis Therapeutics Holdings (NASDAQ:ETTX) In A Good Position To Invest In Growth?
Aug 19Entasis Therapeutics shares rise after lining up ETX0462 poster presentation
Jun 18What Kind Of Shareholders Own Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX)?
Feb 17
Is Entasis Therapeutics Holdings (NASDAQ:ETTX) In A Good Position To Invest In Growth?
Dec 01CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2022 | n/a | n/a | -US$52m |
| Dec 31 2021 | US$2m | US$553k | -US$47m |
| Sep 30 2021 | n/a | n/a | -US$46m |
| Jun 30 2021 | n/a | n/a | -US$45m |
| Mar 31 2021 | n/a | n/a | -US$46m |
| Dec 31 2020 | US$1m | US$537k | -US$50m |
| Sep 30 2020 | n/a | n/a | -US$54m |
| Jun 30 2020 | n/a | n/a | -US$46m |
| Mar 31 2020 | n/a | n/a | -US$46m |
| Dec 31 2019 | US$1m | US$495k | -US$44m |
| Sep 30 2019 | n/a | n/a | -US$38m |
| Jun 30 2019 | n/a | n/a | -US$52m |
| Mar 31 2019 | n/a | n/a | -US$44m |
| Dec 31 2018 | US$2m | US$450k | -US$42m |
| Sep 30 2018 | n/a | n/a | -US$43m |
| Jun 30 2018 | n/a | n/a | -US$34m |
| Mar 31 2018 | n/a | n/a | -US$35m |
| Dec 31 2017 | US$1m | US$430k | -US$30m |
| Dec 31 2016 | US$761k | US$413k | -US$19m |
Compensation vs Market: Manos's total compensation ($USD2.05M) is above average for companies of similar size in the US market ($USD776.58K).
Compensation vs Earnings: Manos's compensation has increased whilst the company is unprofitable.
CEO
Manos Perros (54 yo)
7.2yrs
Tenure
US$2,047,687
Compensation
Dr. Manoussos Perros, Ph D., also known as Manos, serves as the Chief Executive Officer, President & Director at Entasis Therapeutics Inc. Dr. Perros has been President, Chief Executive Officer and Directo...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 7.2yrs | US$2.05m | 0.17% $ 174.7k | |
| Chief Scientific Officer | 7.2yrs | US$998.39k | 0.098% $ 103.0k | |
| Chief Medical Officer | 2.7yrs | US$1.09m | 0.052% $ 54.7k | |
| Interim VP and Interim Principal Financial & Accounting Officer | less than a year | no data | no data | |
| General Counsel | 3.3yrs | no data | 0.35% $ 367.0k | |
| Chief Development Officer | 7.2yrs | US$754.14k | 0.35% $ 365.9k | |
| Chief Pharmaceutical Sciences & Manufacturing Officer | 1.8yrs | no data | 0.35% $ 367.0k | |
| Chief Commercial Officer | less than a year | no data | 0.26% $ 273.7k |
3.0yrs
Average Tenure
55.5yo
Average Age
Experienced Management: ETTX's management team is considered experienced (3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 7.2yrs | US$2.05m | 0.17% $ 174.7k | |
| Independent Director | 4.3yrs | US$153.23k | 0.046% $ 48.2k | |
| Member of Scientific & Clinical Board | 1.9yrs | no data | no data | |
| Independent Director | 4.9yrs | US$49.00k | no data | |
| Member of Scientific & Clinical Board | no data | no data | no data | |
| Member of Scientific & Clinical Board | no data | no data | no data | |
| Independent Director | 2.9yrs | US$123.05k | 0.046% $ 48.2k | |
| Independent Director | 4.9yrs | US$132.33k | 0.046% $ 48.2k | |
| Member of Scientific & Clinical Board | no data | no data | no data | |
| Independent Chairman of the Board | 3.1yrs | US$174.28k | 0.046% $ 48.2k | |
| Member of Scientific & Clinical Board | no data | no data | no data | |
| Member of Scientific & Clinical Board | no data | no data | no data |
4.3yrs
Average Tenure
57.5yo
Average Age
Experienced Board: ETTX's board of directors are considered experienced (4.3 years average tenure).